Astrazeneca (AZN) Payables (2009 - 2026)

Astrazeneca (AZN) has reported Payables for 18 consecutive years, with -$23.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables fell 2.37% year-over-year to -$23.1 billion; the TTM figure through Mar 2026 stood at -$23.1 billion (down 2.37% YoY), while the FY2025 annual figure was -$25.3 billion, down 214.27% from the prior year.
• Payables came in at -$23.1 billion for Q1 2026 at Astrazeneca, up from -$25.9 billion in the prior quarter.
• The five-year high for Payables was $22.1 billion in Q4 2024, with the low at -$25.9 billion in Q4 2025.
• Average Payables over 5 years is -$14.8 billion, with a median of -$20.2 billion recorded in 2024.
• Across the five-year window, Payables jumped 893.59% in 2023 and plunged 217.12% in 2025, its largest moves.
• Year by year, Payables stood at $2.2 billion in 2022, then surged by 893.59% to $21.9 billion in 2023, then advanced by 1.26% to $22.1 billion in 2024, then slumped by 217.12% to -$25.9 billion in 2025, then advanced by 10.89% to -$23.1 billion in 2026.
• According to Business Quant data, Payables over the past three periods registered -$23.1 billion, -$25.9 billion, and -$25.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.